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There is a substantial need to develop new medicines against parasitic diseases via public-private
partnerships. Based on high throughput phenotypic screens of largely protozoal pathogens and bacte-
ria, the Medicines for Malaria Venture (MMV) has recently assembled an open-access ‘Pathogen Box’
containing 400 well-curated chemical compounds. In the present study, we tested these compounds for
activity against parasitic stages of the nematode Haemonchus contortus (barber's pole worm). In an
optimised, whole-organism screening assay, using exsheathed third-stage (xL3) and fourth-stage (L4)
larvae, we measured the inhibition of larval motility, growth and development of H. contortus. We also
studied the effect of the ‘hit’ compound on mitochondrial function by measuring oxygen consumption.
Among the 400 Pathogen Box compounds, we identiﬁed one chemical, called tolfenpyrad (compound
identiﬁcation code: MMV688934) that reproducibly inhibits xL3 motility as well as L4 motility, growth
and development, with IC50 values ranging between 0.02 and 3 mM. An assessment of mitochondrial
function showed that xL3s treated with tolfenpyrad consumed signiﬁcantly less oxygen than untreated
xL3s, which was consistent with speciﬁc inhibition of complex I of the respiratory electron transport
chain in arthropods. Given that tolfenpyrad was developed as a pesticide and has already been tested for
absorption, distribution, excretion, biotransformation, toxicity and metabolism, it shows considerable
promise for hit-to-lead optimisation and/or repurposing for use against H. contortus and other parasitic
nematodes. Future work should assess its activity against hookworms and other pathogens that cause
neglected tropical diseases.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Compounded by massive global food and water shortages and
climate change, parasitic illnesses, including neglected tropical
diseases (NTDs; WHO, 2015), have a devastating, long-term impact
on human and animal health and welfare worldwide, and thus
represent a major global challenge. Together, NTDs infect more
than one billion people worldwide, resulting in an estimated loss of
26 million disability-adjusted life years (Hotez et al., 2014).
Despite their adverse socioeconomic impact, there are major
limitations in the diagnosis, treatment and control of NTDs.
Currently, there are no commercial vaccines available against most
of these diseases (Pedrique et al., 2013; Hotez et al., 2016), diag-
nostic methods frequently suffer from insufﬁcient speciﬁcity and
sensitivity (Utzinger et al., 2012; Assefa et al., 2014), and treatments
are often not highly effective and/or are toxic (Castro et al., 2006;
Witschel et al., 2012; Molina et al., 2015). In addition, often the
small numbers of drugs (or drug classes) frequently used, limited
use of combination drug therapies and the implementation of mass
drug administration programs bear the risk of drug resistance
emerging in some groups of target pathogens (Humphries et al.,
2012; Witschel et al., 2012; Webster et al., 2014). Therefore, the
development of new drugs is crucial to ensure effective and sus-
tained treatment and control into the future.
In spite of some success through the discovery of, for example,
monepantel (Kaminsky et al., 2008; Prichard and Geary, 2008) and
derquantel (Little et al., 2011), progress in discovering new drugs
against parasitic worms of animal health importance has been
relatively poor. Likely reasons for limited success beyond the lack of
resources include an over-conﬁdence in the validation of molecular
targets (enzymes and receptors) and in studying an inappropriate
developmental stage of a pathogen. However, key gaps include a
lack of readily available curated sets of compounds for targeted
screening and subsequent evaluation, limited cooperation among
different areas (including parasitology, drug discovery, medicinal
chemistry and safety evaluation) which are essential to ﬁnd start-
ing points for drug discovery, and to bring them to tangible and
translational outcomes and outputs.
In the late 1990s, an innovative collaboration model for research
and development for neglected diseases emerged in the form of
public-private partnerships (PPPs) that came to be known as
product development partnerships (PDPs). A key example is the
Medicines for Malaria Venture (MMV), created from a desire to
catalyse the discovery development and delivery of new medicines
against malaria. Over the last decade, almost seven million com-
pounds have been tested in phenotypic assays against malaria, and
this has resulted in a solid pipeline of new preclinical and clinical
candidates. In addition, an open science initiative has made many
of these structures available, and a collection of 400 key malaria
phenotypic ‘hits’, called the ‘Malaria Box’, was launched in 2013.
Building on this model, in December 2015, MMV took this a stage
further, with an initiative to stimulate the discovery of drugs for
neglected parasitic diseases. The ‘Pathogen Box’ (www.
pathogenbox.org), contains 400 diverse drug-like molecules, and
is provided at no cost to research groups.
Each of the 400 compounds in the ‘Pathogen Box’ has conﬁrmedactivity against one or more key pathogens that cause some of the
most socioeconomically important diseases worldwide, including
tuberculosis, malaria, sleeping sickness, leishmaniasis, schistoso-
miasis, hookworm disease, toxoplasmosis and cryptosporidiosis. In
addition, all compounds have been tested for cytotoxicity, with
compounds included in the library being at least 5-fold more se-
lective for the pathogen than its mammalian host. The complete set
of compounds is dispatched to laboratories around the world to
boost drug discovery efforts. This initiative provided us with a
unique opportunity to assess these curated compounds for nema-
tocidal activity in a recently developed whole-organism screening
assay (Preston et al., 2015, 2016). Our aim was to rapidly screen all
400 compounds against parasitic stages of the barber's pole worm,
Haemonchus contortus, and to identify hit compounds and charac-
terise/assess them for further evaluation as nematocidal candi-
dates. This worm was used because it is one of the best-studied
members of a large order (Strongylida) of socioeconomically
important nematodes of animals, including humans, because there
is extensive information available on its biology and molecular
biology, and because its genome and developmental transcriptome
have been characterised in detail (Gasser and von Samson-
Himmelstjerna, 2016), providing a foundation for drug discovery
efforts.2. Materials and methods
2.1. Procurement of H. contortus
The Haecon-5 strain of Haemonchus contortus, which is partially
resistant to benzimidazoles (Dr Jody Zawadzki, personal commu-
nication), was maintained in experimental sheep as described
previously (Schwarz et al., 2013; Preston et al., 2015) and in
accordance with the institutional animal ethics guidelines (permit
no. 1413429; The University of Melbourne, Australia). L3s were
produced from H. contortus eggs by incubating faeces from infected
sheep at 27 C for 1 week (Preston et al., 2015), sieved through
nylon mesh (pore size: 20 mm) to remove debris or dead larvae and
then stored at 10 C for a maximum of 3 months. For screening and
basal oxygen consumption measurements (see following sub-
sections), L3s were exsheathed and sterilised in 0.15% v/v sodium
hypochlorite (NaClO) at 37 C for 20 min (Preston et al., 2015).
Thereafter, xL3s were washed ﬁve times in sterile physiological
saline by centrifugation at 600 g (5 min) at 22e24 C. Then, xL3s
were immediately suspended in Luria Bertani medium [LB: 10 g of
tryptone (cat no. LP0042; Oxoid, England), 5 g of yeast extract (cat
no. LP0042; Oxoid) and 5 g of NaCl (cat. no. K43208004210; Merck,
Denmark)] in 1 l of reverse-osmosis deionised water). LB was
autoclaved and supplemented with 100 IU/ml of penicillin, 100 mg/
ml of streptomycin and 2.5 mg/ml of amphotericin (Fungizone,
antibiotic e antimycotic; cat. no. 15240-062; Gibco, USA); this
supplemented LB was designated LB*. Fourth-stage larvae (L4s)
were produced from xL3s in vitro for 7 days at 38 C and 10% CO2, as
described by Preston et al. (2015, 2016).
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The Pathogen Box contains 400 compounds representing com-
pounds that are active against one or more of 12 distinct pathogens
(http://www.pathogenbox.org/about-pathogen-box/supporting-
information). Individual compounds had only been tested to
conﬁrm activity against the pathogen for which the compounds
wereﬁrst reported to be active, and have not been tested against the
other pathogens represented in the Pathogen Box. All compounds
have been tested for cytotoxicity; typically, they are ﬁve-fold less
potent against a human ﬁbroblast cell line (MRC-5) than the path-
ogen (cf. Table 1); toxicity values are within levels considered
acceptable for an initial drug discovery programme (www.
pathogenbox.org/about-pathogen-box/supporting-information).
Each of the 400 compounds was prepared as described previously
(Preston et al., 2015) and screened (in triplicate) at a concentration
of 20 mMonxL3s ofH. contortus in 96-wellmicroculture plates using
two reference-control compounds, moxidectin and monepantel
(Preston et al., 2015, 2016). In brief, compounds were dissolved to a
stock concentration of 10 mM in dimethyl sulfoxide (DMSO, Ajax
Finechem, Australia). Compounds were individually diluted to the
ﬁnal concentration of 20 mMusing LB*, and dispensed (in triplicate)
intowells of themicroculture plates using amultichannel pipette. In
addition, the negative-controls (LB* and LB*þ 0.5% DMSO; six wells
each), and positive-controls (ﬁnal concentration of 20 mM of mon-
epantel [Zolvix, Novartis Animal Health, Switzerland] and 20 mM of
moxidectin [cydectin, Virbac, France]) were dispensed in triplicate
wells. Then, xL3s (~300/well) were dispensed into wells of the plate
using an automated multichannel pipette (Viaﬂo Assist/II, Integra
Biosciences, Switzerland). Following an incubation for 72 h at 38 C
and 10%CO2, a video recording (5 s)was taken of eachwell of the 96-
well microculture plate (containing xL3s) using a grey-scale camera
(Rolera bolt, Q imaging Scientiﬁc Coms, Canada), and amotorised X-
Y axis stage (BioPoint 2, Ludl Electronics Products, USA). Individual
videos were processed to calculate a motility index (MI) using an
algorithmdescribed previously (Preston et al., 2015, 2016).MIswere
normalised to the positive- and negative-controls (to remove plate-
to-plate variation) using the programPrism (v.6 GraphPad Software,
USA). A compound was recorded as having activity if it reduced xL3
motility by  70% after 72 h of incubation.
2.3. Dose-response assessments of active compounds on xL3 and L4
motility, and L4 growth and development
Anti-xL3 activity of any ‘hit’ compound was conﬁrmed, and half
maximum inhibitory concentration (IC50) values estimated from
dose-response curves (24 h, 48 h and 72 h). Compounds that
reduced the motility of xL3s were also tested for their ability to
inhibit the development of xL3s to L4s, the motility of L4s and/or
their ability to retard L4 growth, as described previously (Preston
et al., 2015, 2016). In brief, growth retardation and morphological
alterations in L4s exposed for 48 h to LB* containing either 1%
DMSO (negative-control), 100 mM of each tolfenpyrad (test com-
pound), moxidectin (positive-control) or monepantel (positive-
control) were assessed microscopically (20e100 magniﬁcation).
For each treatment, the mean width of 30 L4s ± the standard error
of the mean (SEM) was calculated, and a non-parametric (Kruskal-
Wallis) one-way ANOVA and Dunn's multiple comparison test was
used to calculate statistical difference between treatments. All as-
says (xL3 motility, and L4 development, growth and motility) were
performed in triplicate, between 3 and 5 times on different days. To
determine IC50 values, the data from each assay (xL3 motility, L4
motility and development) were converted to a percentage with
reference to the negative-control (LB* þ 0.5% DMSO), and IC50
values determined using a variable slope four-parameter equation,constraining the top value to 100% and using a least squares (or-
dinary) ﬁt model (v.6 GraphPad Software). Selectivity indices (SIs)
were calculated using a recognised formula (SI ¼ human ﬁbroblast
(MRC-5) cells IC50/H. contortus IC50; Fisher et al., 2014) employing
cytotoxicity data linked to the Pathogen Box compounds.2.4. Measurement of basal oxygen consumption
Following standardization using an established protocol, the
basal oxygen consumption (‘respiratory’) rate in xL3s was
measured using the Seahorse XF24 ﬂux analyser (Seahorse Bio-
sciences, USA) (McGee et al., 2011). In brief, 450 ml of LB* þ 1%
DMSO containing 100 mM of tolfenpyrad (‘hit’ compound) or
100 mMofmoxidectin (control; not known to inhibit respiration), or
LB* þ 1% DMSO alone (untreated control) were transferred in
quadruplicate to the wells of a 24-well plate (Seahorse XF24). Then,
1000 xL3s in 50 ml LB* were added to the wells, and the plates pre-
incubated for 2 h, equilibrated for 30 min and oxygen consumption
measured using the ﬂux analyser. Seven measurements were taken
over a 1 h-period (protocol: 2 min-mix, 2 min-pause and 4 min-
measure; McGee et al., 2011). Experiments were repeated twice.
A two-way repeated measures ANOVA with a Dunnett's multiple
comparison test (v.6 GraphPad Prism) was used to assess the sta-
tistical difference in oxygen consumption between treated and
untreated xL3s.3. Results
In the primary screen of the 400 compounds (Fig. 1; Supple-
mentary ﬁle 1), one compound (tolfenpyrad; Compound ID:
MMV688934; batch: MMV688934-01; pubchem.ncbi.nlm.nih.gov/
compound/10110536) was recorded to inhibit xL3 motility
by  70%. Although there are benzimidazole-based compounds in
the Pathogen Box, nematocidal activity was not detected using this
70% threshold, because the Haecon-5 strain of H. contortus is
partially resistant to this class of chemicals. Subsequent assays
using xL3s and L4s of H. contortus showed that the potency of tol-
fenpyrad, measured as IC50 values, ranged from 0.02 to 3 mM (Fig. 1;
Table 1). In comparison to moxidectin andmonepantel, tolfenpyrad
was able to reduce motility earlier than monepantel, with inhibi-
tion occurring after 2 h of exposure and an IC50 value of 2.3 mM at
24 h compared with 52.1 mM for monepantel (Fig. 3). Tolfenpyrad
and moxidectin were found to have a similar inhibitory effect on
xL3 motility at the time points tested (Table 1). Furthermore, when
examining the inhibitory activity of the compounds on L4 motility,
tolfenpyrad and moxidectin had lower IC50 values at 24 h, 48 h and
72 h compared with that of monepantel (Table 1). In the L4
development assay, tolfenpyrad had a greater inhibitory effect on
the development of xL3 to L4 (IC50 of 0.06 mM) than did moxidectin
and monepantel (IC50 of 12.3 mM and 0.4 mM, respectively). Light
microscopic examination of parasitic larvae revealed morpholog-
ical damage (shrivelled and granulated appearance) in L4s
following exposure in vitro (48 h) to tolfenpyrad and monepantel
(Fig. 2), but not in xL3s (data not shown). L4s exposed to tol-
fenpyrad were signiﬁcantly thinner than ‘untreated’ controls, and
had a similar width to moxidectin-exposed, but not as pronounced
as monepantel-exposed larvae (Fig. 2). Finally, it was assessed
whether tolfenpyrad would inhibit respiration in H. contortus xL3s,
as it does in arthropods by targeting complex I of the respiratory
electron transport chain (Song et al., 2013), by measuring oxygen
consumption over time (Fig. 3). The results showed that
tolfenpyrad-treated xL3s consumed substantially (P < 0.05) less
oxygen than both moxidectin-treated and untreated xL3s (Fig. 3)
(Table 1).
Table 1
In vitro activity of tolfenpyrad on the motility of exsheathed third-stage (xL3) and
fourth-stage (L4) larvae of Haemonchus contortus (after 24 h, 48 h and 72 h of
exposure) and on the development of the L4 stage (after 7 days of exposure), in
comparisonwith values for monepantel and moxidectin, as well as cytotoxicity data
for tolfenpyrad.
Bioassay Time Half maximum inhibitory concentration (IC50;
mM)
Tolfenpyrad Monepantel Moxidectin
xL3 motility 24 h 2.3 52 2.5
48 h 3.0 6 2.5
72 h 3.0 0.4 2.3
L4 development 7 days 0.06 0.4 12.3
L4 motility 24 h 0.13 4.3 2.2
48 h 0.06 2.2 0.6
72 h 0.02 3 0.005
Cytotoxicity on human
ﬁbroblast (MRC-5) cellsa
56 na na
a Data from the Laboratory of Microbiology, Parasitology and Hygiene (LMPH),
University of Antwerp, provided to Medicines for Malaria Venture (MMV) to
accompany the Pathogen Box. na ¼ not applicable.
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The screening of the Pathogen Box compounds identiﬁed one
chemical, tolfenpyrad, with major activity against parasitic larval
stages (xL3 and L4) of H. contortus in vitro; IC50 values were com-
parable with those of two commercially available anthelmintics,
monepantel and moxidectin. Tolfenpyrad, a pyrazole-5-
carboxamide insecticide, is the International Organization forFig. 1. The ‘Pathogen Box’ from the Medicines for Malaria Venture (MMV) (Panel A) conta
pathogens that cause some of the most socioeconomically important diseases worldwide
hookworm disease, trichuriasis, schistosomiasis; numbers of chemicals active against differe
show the activity of tolfenpyrad on the motility of exsheathed third-stage (xL3) and fourth-s
the development of the L4 stage (after 7 days of exposure), respectively.Standardization e approved name for 4-chloro-3-ethyl-1-methyl-
N-[4-(p-tolyloxy)benzyl]pyrazole-5-carboxamide (International
Union of Pure and Applied Chemistry, IUPAC), which has the
Chemical Abstracts Service number 129558-76-5. Tolfenpyrad was
included in the MMV ‘Pathogen Box’ based on results from a
compound screen of agro-chemicals, which showed that tol-
fenpyrad has potent and selective in vitro activity against Trypa-
nosoma spp. (Witschel et al., 2012). As a pesticide, tolfenpyrad has
relatively broad activity against egg, larval, nymphal and adult
stages of various arthropods (including Hemiptera, Coleoptera,
Diptera, Lepidoptera, Thysanoptera and Acarina), and has been
applied to various infested crops (Song et al., 2012; Yamaguchi
et al., 2012). This chemical was developed in Japan and was ﬁrst
approved in 2002; it has been registered for commercial use in
several countries other than Japan, including the Dominican Re-
public, Thailand, the United Arab Emirates, Indonesia and the USA
(Yamaguchi et al., 2012).
In the present study, tolfenpyrad was shown to be more potent
against L4s than xL3s based on IC50 values (motility and develop-
ment), with substantial cuticular damage to the L4 but not to the
xL3 stage. Compared with untreated-control L4s, the width of
tolfenpyrad-treated L4s were signiﬁcantly reduced as were mox-
idectin- and monepantel-treated control L4s, indicating that
treatment suppresses parasite growth and development. It is un-
clear whether the difference in potency of tolfenpyrad between the
two larval stages tested is due to variation in drug uptake, as at the
L4 stage has a functioning pharynx (Sommerville, 1966), or the
mode of action. The mode of action of this chemical (as a contact
insecticide and fungicide) is likely linked to the speciﬁc inhibitionins 400 diverse drug-like molecules with conﬁrmed activity against one or more key
, including malaria, toxoplasmosis, cryptosporidiosis, trypanosomiasis, leishmaniasis,
nt pathogen/pathogen groups are indicated in parentheses. The graphs (Panels B to D)
tage (L4) larvae of Haemonchus contortus (after 24 h, 48 h and 72 h of exposure) and on
Fig. 2. Panel A. Images of fourth-stage larvae (L4) exposed for 48 h to LB* containing
either 1% dimethyl sulfoxide (untreated, negative control), 100 mM of each tolfenpyrad,
moxidectin (positive-control) or monepantel (positive-control). Displayed are whole
worm (L4) or anterior, mid-body and posterior regions (20e100magniﬁcation; white
scale bar: 20 mm). Solid, black arrows show structural damage to the cuticle and mouth
of L4s. Panel B. Graph showing the mean widths of L4s under the same experimental
conditions. The data points represent the mean width of 30 individual L4s ± the
standard error of the mean (SEM). A representative graph of two separate experiments
is shown. Signiﬁcance between values (mean ± SEM) was determined using a non-
parametric (Kruskal-Wallis) one-way ANOVA and Dunn's multiple comparison test.
*/** indicate which values are signiﬁcantly different from one another (P < 0.05 and
P < 0.01, respectively).
Fig. 3. Panel A. Motility of exsheathed third-stage larvae (xL3s) of Haemonchus con-
tortus incubated in culture medium (LB* þ 1% DMSO) (untreated), and in the presence
of 100 mM of either tolfenpyrad (‘hit’ compound) or moxidectin (control) at three
distinct time points; at each data point, motility was normalised to time (0 min). Panel
B. Based on results in panel A, oxygen consumption was measured seven times (8 min
each) over a period of 1 h in untreated xL3s, and xL3s treated with the same con-
centration (100 mM) of tolfenpyrad (‘hit’ compound) or moxidectin (control) using a
ﬂux analyser. The mean values from 10 replicates (motility) and 8 replicates (oxygen
consumption) from two separate experiments are shown, with variation between
measurements displayed as a standard error of the mean (SEM). */** indicate values
(mean ± SEM) which are signiﬁcantly different from one another (P < 0.05 and
P < 0.01, respectively), determined using a two-way ANOVA and Dunnett's multiple
comparison test.
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chondria (Lummen, 1998; Song et al., 2013), such that it is effective
against various pests that are resistant to insecticides, including
organophosphates and carbamates, which have modes of action
that are entirely distinct from tolfenpyrad.
To explore whether tolfenpyrad might act as an inhibitor of the
electron transport chain in H. contortus, oxygen consumption was
measured in xL3s in the presence or absence of tolfenpyrad
following a pre-exposure for 2 h to the compound. This approach is
routinely used to evaluate mitochondrial function in Caenorhabditis
elegans andmammalian tissue by detecting oxygen consumption in
real-time using oxygen-sensitive probes (McGee et al., 2011;
Andreux et al., 2014). In the present study, we elected to pre-treat
xL3s of H. contortus for 2 h prior to the initial measurement of
oxygen consumption, as both tolfenpyrad and moxidectin signiﬁ-
cantly inhibit motility following acute exposure. The results
revealed a signiﬁcant decrease in oxygen consumption in xL3s
exposed to tolfenpyrad compared with untreated controls.Similarly, oxygen consumption was lower in tolfenpyrad-treated
than moxidectin-treated xL3s, which was also associated with
reducedmotility following the exposure for 2 h. This discrepancy in
oxygen consumption between these treatments indicates that tol-
fenpyrad is also most likely acting as a complex I mitochondrial
electron transport inhibitor in H. contortus.
Although mainly used against agricultural pests, tolfenpyrad
had not been assessed previously for use against endoparasites,
such as parasitic worms, of animals. A report was prepared by the
Joint FAO/WHOMeeting on Pesticide Residues at the request of the
Codex Committee on Pesticide Residues in 2013 (FAO, 2013). This
report extensively reviewed and appraised many aspects of tol-
fenpyrad, including: (i) acceptable daily intake; (ii) absorption,
distribution, excretion and biotransformation; (iii) toxicity studies
(acute; short and long-term; carcinogenicity; genotoxicity; repro-
ductive, developmental and neural toxicity), and (iv) studies of
metabolites. The main conclusions from this report were: (i) the
acceptable daily intake of tolfenpyrad is 0e0.006 mg/kg in mam-
mals; (ii) following oral administration, tolfenpyrad is rapidly
absorbed, widely distributed and metabolized by the liver, with
88e93% being excreted in the faeces, and (iii) tolfenpyrad was not
found to be carcinogenic, genotoxic or neurotoxic, but was found to
have some reproductive and developmental toxicity. Although
some intoxications (associated with excessive exposure/ingestion)
have been recorded in humans (e.g., Yamaguchi et al., 2012; Hikiji
et al., 2013), well-controlled risk assessment studies in
S. Preston et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 329e334334monogastric mammals (mouse, rat, rabbit and dog) have shown
that the no-observed-adverse-effect levels (NOAELs) of tolfenpyrad
are between 1 and 1.5 mg/kg body weight per day, with lowest-
observed-adverse-effect levels (LOAEL) of 5e21 mg/kg body
weight per day (FAO, 2013). Therefore, based on the evidence
presented in this report and associated literature (see FAO, 2013) as
well as the high selectivity of tolfenpyrad for H. contortus (see
Table 1), we propose to test tolfenpyrad in vivo in sheep against
H. contortus and/or related parasitic nematodes at dosages between
1 and 5 mg/kg body weight. We also propose to assess its activity
in vitro against the hookworms Ancylostoma ceylanicum and Neca-
tor americanus of humans and other NTD pathogens (London
Declaration, 2012). Nonetheless, it will be important to also
extend medicinal chemistry work to establish whether a safer and
more effective derivative of this chemical might be synthesized.
Given that tolfenpyrad was developed as a pesticide and has
already been tested for absorption, distribution, excretion,
biotransformation, toxicity and metabolism, there is considerable
promise for the repurposing of this chemical for use against
H. contortus and other parasitic nematodes. Further work should
now focus on assessing the activity of tolfenpyrad against hook-
worms and other worms that cause NTDs.
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